zoetis inc. - ZTS
ZTS
Close Chg Chg %
150.84 1.41 0.93%
Closed Market
152.25
+1.41 (0.93%)
Volume: 2.15M
Last Updated:
Apr 24, 2025, 3:59 PM EDT
Company Overview: zoetis inc. - ZTS
ZTS Key Data
| Open $150.52 | Day Range 148.00 - 152.58 |
| 52 Week Range 139.72 - 200.19 | Market Cap $67.32B |
| Shares Outstanding 446.06M | Public Float 445.60M |
| Beta 0.93 | Rev. Per Employee N/A |
| P/E Ratio 27.61 | EPS $5.47 |
| Yield 119.01% | Dividend $0.50 |
| EX-DIVIDEND DATE Apr 21, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.85M |
ZTS Performance
| 1 Week | 2.44% | ||
| 1 Month | -6.63% | ||
| 3 Months | -9.67% | ||
| 1 Year | -3.86% | ||
| 5 Years | 20.96% |
ZTS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
20
Full Ratings ➔
About zoetis inc. - ZTS
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
ZTS At a Glance
Zoetis, Inc.
10 Sylvan Way
Parsippany, New Jersey 07054
| Phone | 1-973-822-7000 | Revenue | 9.26B | |
| Industry | Pharmaceuticals: Major | Net Income | 2.49B | |
| Sector | Health Technology | 2024 Sales Growth | 8.333% | |
| Fiscal Year-end | 12 / 2025 | Employees | 13,800 | |
| View SEC Filings |
ZTS Valuation
| P/E Current | 27.611 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 29.81 |
| Price to Sales Ratio | 8.007 |
| Price to Book Ratio | 15.319 |
| Price to Cash Flow Ratio | 25.096 |
| Enterprise Value to EBITDA | 20.292 |
| Enterprise Value to Sales | 8.526 |
| Total Debt to Enterprise Value | 0.086 |
ZTS Efficiency
| Revenue/Employee | 670,724.638 |
| Income Per Employee | 180,144.928 |
| Receivables Turnover | 7.033 |
| Total Asset Turnover | 0.649 |
ZTS Liquidity
| Current Ratio | 1.754 |
| Quick Ratio | 1.079 |
| Cash Ratio | 0.582 |
ZTS Profitability
| Gross Margin | 69.101 |
| Operating Margin | 36.646 |
| Pretax Margin | 33.848 |
| Net Margin | 26.858 |
| Return on Assets | 17.432 |
| Return on Equity | 50.906 |
| Return on Total Capital | 21.496 |
| Return on Invested Capital | 22.69 |
ZTS Capital Structure
| Total Debt to Total Equity | 142.453 |
| Total Debt to Total Capital | 58.755 |
| Total Debt to Total Assets | 47.728 |
| Long-Term Debt to Equity | 113.082 |
| Long-Term Debt to Total Capital | 46.641 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Zoetis Inc. - ZTS
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 7.78B | 8.08B | 8.54B | 9.26B | |
Sales Growth
| +16.49% | +3.91% | +5.74% | +8.33% | |
Cost of Goods Sold (COGS) incl D&A
| 2.46B | 2.60B | 2.71B | 2.86B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 448.00M | 465.00M | 491.00M | 497.00M | |
Depreciation
| 244.00M | 272.00M | 306.00M | 327.00M | |
Amortization of Intangibles
| 204.00M | 193.00M | 185.00M | 170.00M | |
COGS Growth
| +11.14% | +5.68% | +4.07% | +5.54% | |
Gross Income
| 5.31B | 5.48B | 5.83B | 6.40B | |
Gross Income Growth
| +19.16% | +3.09% | +6.54% | +9.63% | |
Gross Profit Margin
| +68.31% | +67.77% | +68.28% | +69.10% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.51B | 2.55B | 2.77B | 3.00B | |
Research & Development
| 508.00M | 539.00M | 614.00M | 686.00M | |
Other SG&A
| 2.00B | 2.01B | 2.15B | 2.32B | |
SGA Growth
| +14.62% | +1.55% | +8.52% | +8.64% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 81.00M | 99.00M | 95.00M | 62.00M | |
EBIT after Unusual Expense
| 2.72B | 2.83B | 2.97B | 3.33B | |
Non Operating Income/Expense
| 2.00M | 64.00M | 220.00M | 45.00M | |
Non-Operating Interest Income
| 6.00M | 50.00M | 105.00M | 106.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 236.00M | 237.00M | 258.00M | 242.00M | |
Interest Expense Growth
| -5.22% | +0.42% | +8.86% | -6.20% | |
Gross Interest Expense
| 256.00M | 258.00M | 285.00M | 281.00M | |
Interest Capitalized
| 20.00M | 21.00M | 27.00M | 39.00M | |
Pretax Income
| 2.49B | 2.66B | 2.94B | 3.13B | |
Pretax Income Growth
| +24.65% | +6.75% | +10.54% | +6.71% | |
Pretax Margin
| +32.00% | +32.87% | +34.36% | +33.85% | |
Income Tax
| 454.00M | 545.00M | 596.00M | 637.00M | |
Income Tax - Current - Domestic
| 346.00M | 595.00M | 376.00M | 710.00M | |
Income Tax - Current - Foreign
| 188.00M | 235.00M | 281.00M | 265.00M | |
Income Tax - Deferred - Domestic
| (94.00M) | (247.00M) | (15.00M) | (339.00M) | |
Income Tax - Deferred - Foreign
| 14.00M | (38.00M) | (46.00M) | 1.00M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 2.03B | 2.11B | 2.34B | 2.50B | |
Minority Interest Expense
| (3.00M) | (3.00M) | (4.00M) | 10.00M | |
Net Income
| 2.04B | 2.11B | 2.34B | 2.49B | |
Net Income Growth
| +24.36% | +3.78% | +10.88% | +6.06% | |
Net Margin Growth
| +26.20% | +26.16% | +27.43% | +26.86% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 2.04B | 2.11B | 2.34B | 2.49B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 2.04B | 2.11B | 2.34B | 2.49B | |
EPS (Basic)
| 4.2943 | 4.5085 | 5.0827 | 5.4734 | |
EPS (Basic) Growth
| +24.66% | +4.99% | +12.74% | +7.69% | |
Basic Shares Outstanding
| 474.35M | 468.89M | 461.17M | 454.20M | |
EPS (Diluted)
| 4.273 | 4.4942 | 5.0706 | 5.4656 | |
EPS (Diluted) Growth
| +24.84% | +5.18% | +12.83% | +7.79% | |
Diluted Shares Outstanding
| 476.72M | 470.38M | 462.27M | 454.85M | |
EBITDA
| 3.25B | 3.39B | 3.56B | 3.89B | |
EBITDA Growth
| +19.96% | +4.37% | +4.92% | +9.24% | |
EBITDA Margin
| +41.81% | +41.99% | +41.67% | +42.02% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 205.00 | |
| Number of Ratings | 20 | Current Quarters Estimate | 1.616 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 6.088 | |
| Last Quarter’s Earnings | 1.40 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 5.92 | Next Fiscal Year Estimate | 6.768 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 15 | 15 |
| Mean Estimate | 1.62 | 1.65 | 6.09 | 6.77 |
| High Estimates | 1.81 | 1.84 | 6.22 | 7.34 |
| Low Estimate | 1.56 | 1.60 | 6.04 | 6.38 |
| Coefficient of Variance | 4.04 | 3.84 | 0.77 | 3.55 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 15 | 15 | 16 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 5 | 5 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Zoetis Inc. - ZTS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Zoetis Inc. - ZTS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 8, 2025 | Roxanne Lagano Executive Vice President | 28,264 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Rimma Driscoll Executive Vice President | 4,959 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Joseph B. Fuller Executive Vice President | 27 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Robert J. Polzer Executive Vice President | 10,624 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Keith Sarbaugh Executive Vice President | 815 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Kristin C. Peck Chief Executive Officer; Director | 57,348 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Wetteny Joseph Chief Financial Officer | 6,174 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Gavin D. K. Hattersley Director | 2,216 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Gavin D. K. Hattersley Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Keith Sarbaugh Executive Vice President | 1,506 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Keith Sarbaugh Executive Vice President | 684 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | Keith Sarbaugh Executive Vice President | 2,039 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $164.65 per share | 335,721.35 |
| Mar 12, 2025 | Willie M. Reed Director | 11,245 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $166.14 per share | 1,868,244.30 |
| Feb 24, 2025 | Jeannette Ferran Astorga Executive Vice President | 4,973 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Rimma Driscoll Executive Vice President | 5,235 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Nicholas Ashton Executive Vice President | 2,218 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Roxanne Lagano Executive Vice President | 8,642 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Kristin C. Peck Chief Executive Officer; Director | 84,711 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Robert J. Polzer Executive Vice President | 13,814 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Joseph B. Fuller Executive Vice President | 8,642 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |